John Hunter Hospital, New Lambton Heights, New South Wales, Australia (Drs Aubin, L. McAuliffe, and Sabdia).
Western Australian Country Health Service, Western Australia, Australia (Dr Williams).
Am J Obstet Gynecol MFM. 2023 Aug;5(8):101024. doi: 10.1016/j.ajogmf.2023.101024. Epub 2023 May 20.
Vaginal progesterone and cervical cerclage are both effective interventions for reducing preterm birth. It is currently unclear whether combined therapy offers superior effectiveness than single therapy. This study aimed to determine the efficacy of combining cervical cerclage and vaginal progesterone in the prevention of preterm birth.
We searched Medline (Ovid), EMBASE (Ovid), PsycINFO (Ovid), CINAHL (EBSCOhost), Cochrane Library (Wiley), and Scopus (from their inception to 2020).
The review accepted randomized and pseudorandomized control trials, nonrandomized experimental control trials, and cohort studies. High risk patients (shortened cervical length <25mm or previous preterm birth) who were assigned cervical cerclage, vaginal progesterone, or both for the prevention of preterm birth were included. Only singleton pregnancies were assessed.
The primary outcome was birth <37 weeks. Secondary outcomes included birth <28 weeks, <32 weeks and <34 weeks, gestational age at delivery, days between intervention and delivery, preterm premature rupture of membranes, cesarean delivery, neonatal mortality, neonatal intensive care unit admission, intubation, and birthweight. Following title and full-text screening, 11 studies were included in the final analysis. Risk of bias was assessed using the Cochrane Collaboration tool for assessing the risk of bias (ROBINS-I and RoB-2). Quality of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) tool.
Combined therapy was associated with lower risk of preterm birth at <37 weeks than cerclage alone (risk ratio, 0.51; 95% confidence interval, 0.37-0.79) or progesterone alone (risk ratio, 0.75; 95% confidence interval, 0.58-0.96). Compared with cerclage only, combined therapy was associated with preterm birth at <34 weeks, <32 weeks, or <28 weeks, decreased neonatal mortality, increased birthweight, increased gestational age, and a longer interval between intervention and delivery. Compared with progesterone alone, combined therapy was associated with preterm birth at <32 weeks, <28 weeks, decreased neonatal mortality, increased birthweight, and increased gestational age. There were no differences in any other secondary outcomes.
Combined treatment of cervical cerclage and vaginal progesterone could potentially result in a greater reduction in preterm birth than in single therapy. Further, well-conducted and adequately powered randomized controlled trials are needed to assess these promising findings.
阴道孕酮和宫颈环扎术都是减少早产的有效干预措施。目前尚不清楚联合治疗是否比单一治疗更有效。本研究旨在确定宫颈环扎术联合阴道孕酮预防早产的疗效。
我们检索了 Medline(Ovid)、EMBASE(Ovid)、PsycINFO(Ovid)、CINAHL(EBSCOhost)、Cochrane 图书馆(Wiley)和 Scopus(从其成立到 2020 年)。
本综述接受了随机和伪随机对照试验、非随机实验对照试验和队列研究。高危患者(宫颈长度缩短<25mm 或既往早产)接受宫颈环扎术、阴道孕酮或两者联合预防早产。仅评估单胎妊娠。
主要结局为<37 周分娩。次要结局包括<28 周、<32 周和<34 周、分娩时的胎龄、干预与分娩之间的天数、早产胎膜早破、剖宫产、新生儿死亡率、新生儿重症监护病房入院、插管和出生体重。经过标题和全文筛选,11 项研究纳入最终分析。使用 Cochrane 协作组评估偏倚风险工具(ROBINS-I 和 RoB-2)评估偏倚风险。使用 GRADE(推荐评估、制定与评价)工具评估证据质量。
与单独宫颈环扎术(风险比,0.51;95%置信区间,0.37-0.79)或单独孕酮(风险比,0.75;95%置信区间,0.58-0.96)相比,联合治疗与<37 周早产风险降低相关。与单独宫颈环扎术相比,联合治疗与<34 周、<32 周或<28 周早产、新生儿死亡率降低、出生体重增加、胎龄增加和干预与分娩之间的时间间隔延长相关。与单独使用孕酮相比,联合治疗与<32 周、<28 周早产、新生儿死亡率降低、出生体重增加和胎龄增加相关。其他次要结局无差异。
宫颈环扎术联合阴道孕酮治疗可能比单一治疗更能有效降低早产率。此外,需要进行精心设计和充分有效的随机对照试验来评估这些有前途的发现。